The striking clinical evidence of dostarlimab anti-PD1 monotherapy eliminating 100% of locally advanced rectal cancer in a small cohort of patients with MMR-deficient rectal tumors may revolutionize our therapeutic policies against rectal cancer [6]. This evidence concerns the gene PDCD1 and rectal cancer.